July 25 marked an important milestone for Sun Pharma, India’s largest drug maker by revenue. The US FDA approved Leqselvi (deuruxolitinib), a new pill to treat severe alopecia areata in adults. Leqselvi is seen by experts as a drug with a potential to beat its mighty opponents like Pfizer and Eli Lilly in the US.
The approval comes at a juncture when global sales of Sun Pharma’s specialty drugs crossed a billion dollars, gradually bulging into a.
